Uncategorized

Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China

Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China

Published

on

The combined business entity with Boundless Bio, which will carry Serapha Bio’s name and fold in Boundless Bio, will focus on the development of a gene editor for alpha-1 antitrypsin deficiency.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version